Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) - Total Liabilities
Based on the latest financial reports, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) has total liabilities worth $614.48 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Shanghai Shenqi Pharmaceutical Investmen to assess how effectively this company generates cash.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B - Total Liabilities Trend (2015–2024)
This chart illustrates how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's total liabilities have evolved over time, based on quarterly financial data. Check 900904 financial resilience to evaluate the company's liquid asset resilience ratio.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B Competitors by Total Liabilities
The table below lists competitors of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Allbirds Inc
NASDAQ:BIRD
|
USA | $67.98 Million |
|
KNOREX LTD.
NYSE MKT:KNRX
|
USA | $9.78 Million |
|
Shreyans Industries Limited
NSE:SHREYANIND
|
India | Rs2.02 Billion |
|
KPS Consortium Bhd
KLSE:9121
|
Malaysia | RM180.13 Million |
|
Auris Minerals Ltd
AU:AUR
|
Australia | AU$253.26K |
|
Pyramid AG
XETRA:M3BK
|
Germany | €32.68 Million |
|
Advanced Connection Technology
TWO:3492
|
Taiwan | NT$351.89 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shanghai Shenqi Pharmaceutical Investmen stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (2015–2024)
The table below shows the annual total liabilities of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $689.01 Million | -22.48% |
| 2023-12-31 | $888.77 Million | -12.38% |
| 2022-12-31 | $1.01 Billion | +34.09% |
| 2021-12-31 | $756.45 Million | -1.79% |
| 2020-12-31 | $770.28 Million | -13.90% |
| 2019-12-31 | $894.60 Million | +69.51% |
| 2018-12-31 | $527.74 Million | -6.65% |
| 2017-12-31 | $565.34 Million | -0.39% |
| 2016-12-31 | $567.56 Million | +47.43% |
| 2015-12-31 | $384.98 Million | -- |
About Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fiel… Read more